World Journal of Gastrointestinal Oncology, published by BAISHIDENG PUBLISHING GROUP INC, stands as a pivotal resource in the evolving fields of gastroenterology and oncology, particularly focused on the intricate relationship between gastrointestinal disorders and cancer. Established in 2014, the journal continues to publish influential research, boasting a commendable Q2 ranking in both the gastroenterology and oncology categories for 2023, which underscores its importance in these critical medical domains. With a diverse range of topics and studies, it serves as an essential platform for researchers, healthcare professionals, and students aiming to stay informed about the latest advancements and innovations in gastrointestinal oncology. Though currently not classified as open access, the journal's rigorous peer-review process ensures the dissemination of high-quality research that significantly contributes to clinical practice and patient care. Its positioning in the Scopus rankings also highlights its competitive standing within the scientific community, fostering discussions that are crucial for advancing both fields. Explore the latest insights and findings to enhance your understanding and contribute to the ongoing dialogue in gastrointestinal health and oncology.

Hepatobiliary & Pancreatic Diseases International, an esteemed journal published by Elsevier, stands as a vital resource within the field of gastroenterology and hepatology. Established in 2002, this journal has developed a significant reputation, currently ranked in the second quartile (Q2) in both categories as of 2023, showcasing its commitment to high-quality research and clinical studies. Based in Singapore, Hepatobiliary & Pancreatic Diseases International serves as an essential platform for researchers, clinicians, and healthcare professionals to share innovative findings, therapeutic approaches, and advancements in the understanding of hepatobiliary and pancreatic diseases. Although the journal does not currently offer Open Access, its rigorous peer-review process ensures that published articles maintain the highest scientific standards, fostering knowledge dissemination among the global research community. With a convergence period extending to 2024, this journal continues to play a pivotal role in enhancing the understanding and treatment of complex gastrointestinal conditions, making it a must-read for anyone engaged in this dynamic field.

CURRENT TREATMENT OPTIONS IN ONCOLOGY, published by Springer, is a premier academic journal dedicated to disseminating cutting-edge research and advancements in the field of oncology and pharmacology. With a commendable impact factor and ranked in the Q1 category in both oncology and pharmacology for 2023, this journal positions itself as a leading resource for researchers, healthcare professionals, and students alike, offering insightful reviews and original articles that critically evaluate treatment methodologies and clinical practices. Covering a wide scope of topics from early detection to innovative therapies, it fosters the translation of research findings into clinical applications. With its convergence years spanning from 2000 to 2024, CURRENT TREATMENT OPTIONS IN ONCOLOGY continues to be at the forefront of oncological research, providing a platform for scholars to explore the latest therapeutic options and improve patient outcomes. Highly regarded in the academic community, this journal is essential for anyone looking to stay informed about the dynamic landscape of cancer treatment.

Clinical and Molecular Hepatology, published by the Korean Association for the Study of Liver, stands at the forefront of hepatology, offering a significant platform for research and innovation in liver diseases. Established in 1995 as an open access journal, it aims to disseminate high-quality research that spans the fields of hepatology, molecular biology, and medicine. With an impressive impact factor ranking it in the Q1 category for 2023 in both Hepatology and Molecular Biology, the journal facilitates a rich exchange of knowledge among professionals, researchers, and students globally. With its dedicated coverage from 2012 to 2024 and exceptional Scopus rankings placing it within the top 10% of journals in its field, Clinical and Molecular Hepatology is an indispensable resource for advancing the understanding and treatment of liver conditions. Located in Seoul, South Korea, the journal emphasizes rigorous peer review and is committed to enhancing clinical practice and molecular research, making it an ideal venue for groundbreaking studies in liver health.

World Journal of Clinical Oncology, published by BAISHIDENG PUBLISHING GROUP INC, stands as a vital resource in the realm of oncology, providing a dedicated platform for the dissemination of cutting-edge research and clinical advancements. With an ISSN of 2218-4333, this journal facilitates a comprehensive exploration of modern oncology challenges and breakthroughs, targeting researchers, healthcare professionals, and students alike. Although it operates under the traditional subscription model, the impactful nature of its content is reflected in its notable ranking of 60 out of 334 in the category of Medicine _ Oncology, placing it in the 82nd percentile among peer publications. Covering significant topics in clinical oncology from 2014 to 2018, the journal has been instrumental in addressing evolving oncology practices and patient care innovations. By publishing high-quality studies, it remains an essential tool for advancing knowledge and fostering collaboration within the global oncology community.

Liver Cancer is a premier, peer-reviewed journal dedicated to the comprehensive study and advancement of knowledge surrounding liver neoplasms. Published by KARGER and headquartered in Switzerland, this journal has been an open-access platform since 2012, providing researchers with invaluable insights into the rapidly evolving field of hepatology and oncology. With an impressive impact factor that places it in the Q1 category for both Hepatology and Oncology in 2023, Liver Cancer stands out as a high-impact conduit for groundbreaking research, ranking #19 out of 404 in Medicine _ Oncology and #6 out of 82 in Medicine _ Hepatology according to Scopus. Researchers, practitioners, and students are encouraged to engage with the journal's content, which encompasses clinical studies, basic research, and reviews that contribute significantly to understanding liver cancer dynamics, diagnosis, and treatment strategies. This journal not only facilitates the dissemination of knowledge but also fosters collaboration in a well-established and impactful global scientific community.

Hepatology International is a premier academic journal dedicated to advancing the field of liver research and hepatology. Published by SPRINGER, this journal boasts a prestigious Q1 ranking in Hepatology as of 2023, underscoring its commitment to high-quality research dissemination. The journal’s scope encompasses a wide range of topics related to liver disease, including clinical, translational, and basic science studies. With its impact factor reflecting its relevance and influence in the field, Hepatology International serves as an essential resource for researchers, clinicians, and students aiming to keep abreast of the latest developments and breakthroughs. Though traditionally a subscription-based journal, it offers a vast array of insightful articles that contribute significantly to our understanding of hepatological conditions. The journal continues its trajectory of growth since its inception in 2008, anticipating a convergence of knowledge and innovation through to 2024. Located in the heart of New York City, this journal not only represents a crucial platform for global hepatology research but also fosters a collaborative community of experts dedicated to improving liver health worldwide.

Hepatology Communications, published by Lippincott Williams & Wilkins, serves as a pioneering platform in the field of hepatology, dedicated to advancing the understanding of liver diseases and treatments. Since its inception in 2017, this open access journal has rapidly gained recognition, achieving an impressive Q1 ranking in Hepatology as of 2023, and appealing to a diverse audience of researchers, clinicians, and students alike. With its focus on high-quality research and clinical studies, the journal aims to facilitate impactful discussions and disseminate vital findings that address the challenges faced in liver health. Operating out of the United States, and accessible globally, Hepatology Communications is committed to fostering a collaborative research environment and enhancing the visibility of scholarly work in hepatology, ultimately driving forward innovations in patient care and treatment strategies.

Clinical Lymphoma Myeloma & Leukemia is a prestigious journal dedicated to the study and treatment of hematologic malignancies, offering a vital platform for researchers and healthcare professionals in the fields of oncology, hematology, and cancer research. Published by CIG MEDIA GROUP, LP, this journal has established itself as a crucial resource since its inception in 2010, with a continuous commitment to disseminating knowledge until at least 2024. With an impact factor that objectively reflects its influence, it is rated in Q3 quartiles in both Cancer Research and Hematology as well as in Oncology as of 2023. Researchers can access a wealth of articles and studies that explore various dimensions of lymphoma, myeloma, and leukemia, thus fostering an environment of collaboration and innovation. Although it currently does not offer full open access, its extensive archive and rigorous peer-review process ensure the publication of high-quality research, making it an essential resource for anyone dedicated to advancing the science and practice of treating blood cancers.

Clinical and Experimental Hepatology is a pivotal journal dedicated to advancing the field of hepatology, providing a platform for researchers, clinicians, and students to disseminate and explore groundbreaking findings. Published by TERMEDIA PUBLISHING HOUSE LTD in Poland, this journal serves as a vital resource for professionals seeking to enhance their knowledge and contributions in the realm of liver diseases and their management. With an impact factor reflective of its growing influence—ranking Q3 in Hepatology for the year 2023 and holding the 49th position out of 82 in Scopus Medicine Hepatology ranks—this publication underscores the significance of innovative research in this specialized domain. While it currently operates through a subscription model rather than open access, it bridges the gap in hepatological literature by featuring a diverse array of scholarly articles, case reports, and reviews from 2015 to 2024. Researchers and health professionals alike will find valuable insights that can enhance clinical practice and inform future studies, solidifying its importance in the hepatology community.